Natural products as a source of cytotoxic warheads in antibody-drug conjugates
Antibody-drug conjugates (ADCs) are one of the most rapidly expanding classes of oncology therapeutics. Till now, 11 ADCs have been approved by USFDA, with the first ADC approval of gemtuzumab ozogamicin (Mylotarg) in 2000. A large number of ADCs are being evaluated in different stages of clinical t...
Saved in:
Published in | Natural product research Vol. 37; no. 17; pp. 2973 - 2985 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Abingdon
Taylor & Francis
02.09.2023
Taylor & Francis Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Antibody-drug conjugates (ADCs) are one of the most rapidly expanding classes of oncology therapeutics. Till now, 11 ADCs have been approved by USFDA, with the first ADC approval of gemtuzumab ozogamicin (Mylotarg) in 2000. A large number of ADCs are being evaluated in different stages of clinical trials and pre-clinical studies. Interestingly, the cytotoxic warheads of the all approved ADCs, as well as clinical and preclinical candidates, belong to different classes of natural products viz. calicheamicins, auristatins, maytansinoids, camptothecin derivatives, pyrolidobenzodiazepines (PBDs), and duocarmycins, etc. Herein, a review of the natural product-based cytotoxic warheads, briefly discussing their source, modifications, and mechanism of action, has been conducted. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1478-6419 1478-6427 |
DOI: | 10.1080/14786419.2022.2138872 |